Several studies assessed HER2 oncogene and protein expression in NSCLC, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, and three distinct types of HER2 changes have been identified: protein overexpression, gene amplification, and mutations. This evidence concerns the gene ERBB2 and adenocarcinoma.